• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Cancer diagnostic detects unique mutations in small amount of blood

August 14, 2017 By Sarah Faulkner

Stanford UniversityResearchers from Stanford University have developed a new diagnostic tool that can detect genetic mutations in small amounts of tumor-derived DNA circulating in a patient’s blood sample.

The single color digital PCR assay needs a fraction of a tube of blood and can successfully detect three mutation-bearing molecules in a single reaction, according to the report published in The Journal of Molecular Diagnostics.

“For monitoring patient tumors, only a handful of blood tests are available which are limited to only several types of cancers,” lead investigator Dr. Hanlee Ji said in prepared remarks. “Nearly all cancer patients require monitoring by whole body imaging, which can be costly, complex, and time-consuming. In contrast, molecular tests like the one we have developed will enable patients to be monitored at every visit, and thus have the potential for quickly tracking cancer growth and spread. Moreover, the test’s rapid turnaround and relatively low cost, especially compared to next-generation DNA sequencing, provide a potential opportunity for universal monitoring of more patients than is currently done.”

The team of Stanford researchers used the test to assess samples from six patients – five colorectal cancer patients and one patient with cholangiocarcinoma.

The scientists reported that they were able to detect tumor-derived circulating DNA in three patients and, in one patient, the test was able to identify the presence of three different mutations.

The three patients whose samples did not show elevated levels of tumor-derived DNA were actively undergoing treatment at the time of collection, the researchers noted.

The single-color digital PCR assay offers a competitive edge over other tools for analysis of ciculating tumor DNA, the team reported, because the test doesn’t rely on pre-amplification, which can introduce errors.

“This test is simple enough to set up and analyze without extensive training, and therefore, it can be implemented by anyone, making it highly accessible to any laboratory,” lead author Christina Wood Bouwens said. “It has been truly motivating to work with a technology that will help transform the way that we monitor and treat individuals with cancer. I am excited to share our findings with the cancer research community.”

See the best minds in medtech live at DeviceTalks Boston on Oct. 2. 

Filed Under: Diagnostics, Featured, Oncology, Research & Development Tagged With: Stanford University

IN CASE YOU MISSED IT

  • FDA approves first targeted infusion therapy for HER2-low breast cancer
  • Abbott, WeightWatchers partner on diabetes care
  • Insulet up on Q2 sales beat, raised full-year guidance
  • Aptar acquires Orbital dry powder inhaler license
  • Tandem sinks on Q2 misses, slashed sales guidance

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS